ExodusPoint Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-14,969
Closed -$148K – 1800
2026
Q2
$148K Sell
14,969
-50,794
-77% -$425K ﹤0.01% 1443
2026
Q1
$403K Buy
+65,763
New +$547K ﹤0.01% 1246
2024
Q3
– Sell
-3,601
Closed -$48K – 1722
2024
Q2
$48K Buy
+3,601
New +$107K ﹤0.01% 1449
2023
Q3
– Sell
-703
Closed -$52K – 1791
2023
Q2
$52K Sell
703
-20,421
-97% -$1.21M ﹤0.01% 1774
2023
Q1
$1.12M Buy
+21,124
New +$1.34M 0.01% 1104
2022
Q3
– Sell
-7,099
Closed -$676K – 1968
2022
Q2
$676K Sell
7,099
-12,176
-63% -$1.49M 0.01% 1248
2022
Q1
$3.11M Buy
19,275
+17,935
+1,338% +$3.49M 0.04% 578
2021
Q4
$445K Buy
+1,340
New +$637K ﹤0.01% 1482

Other funds holding DNA

ExodusPoint Capital Management's DNA Position: Q3 2026 in Review

ExodusPoint Capital Management sold out of Ginkgo Bioworks (DNA) in Q3 2026, closing a stake of 14,969 shares — an estimated $148K sold.

ExodusPoint Capital Management first reported a position in DNA in Q4 2021 and held it in 8 quarters. The position peaked at $3.11M in Q1 2022. 185 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • ExodusPoint Capital Management reported no remaining Ginkgo Bioworks position as of Q3 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 14,969 Ginkgo Bioworks shares in Q3 2026, an estimated $148K.
  • ExodusPoint Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 8 quarters.
  • ExodusPoint Capital Management's Ginkgo Bioworks position peaked at $3.11M in Q1 2022.
  • 185 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.